Interim report
Page 1
Neuland Laboratories Limited 11th floor (5th level), Phoenix IVY Building, Plot No.573A-I11, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CONTACT 040 67611600 / 67611700 neuland@neulandlabs.com neulandlabs.com November 3, 2026 To BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai-400 001 Scrip Code: 524558 Dear Sir/Madam, I( neuland The National Stock Exchange of India Ltd Exchange Plaza, Sandra Kurla Complex Sandra (E), Mumbai -400 001 Scrip Code: NEULANDLAB; Series: EQ Sub: Outcome of Board Meeting Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, i.e. November 3, 2026, have considered and approved the following: A. Financial Results Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2026. A copy of the Unaudited Financial Results for the quarter and half year ended September 30, 2026, together with the limited review rep9rts (Standalone & Consolidated) by the Statutory Auditors of the Company are enclosed herewith. B. Capital expenditure of ~ 47 .1 crores towards the acquisition of a land parcel admeasuring Ac.6-00 Gts situated at Domadugu Village, Sangareddy District, Telangana., including other related expenditure. The requisite details are as under: a. Existing Capacity NIA b. Existing Capacity Utilization NIA c. Proposed Capacity Addition N/A d. Period within which the proposed capacity is to be added N/A e. Investment required ~ 47.1 crores (incl GST) f. Mode of financing Through internal accruals g. Rationale For future capacity expansion The meeting of Board of Directors of the Company commenced at 9:30 a.m. and concluded at 3.34 p.m. The above information will also be available on the website of the Company at www.neulandlabs .. com. This is for your information and records. Thanking you, Yours Sincerely, For Neuland Labo ~- Sarada Bhamidip Company Secreta Encl: As above REGISTERED OFFICE: 11th floor (5th level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CIN No. L85195TG1984PLC004393
Page 2
MS KA & Associates LLP (Formerly known as MS KA ft Associates) Chartered Accountants 1101 /B, Manjeera Trinity Corporate JNTU-Hitech City Road, Kukatpally Telangana, Hyderabad 500072, INDIA Independent Auditor's Review Report on consolidated unaudited financial results of Neuland Laboratories Limited for the quarter and year to date pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Neuland Laboratories Limited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Neuland Laboratories Limited ("the Holding Company"), its subsidiaries, (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations"). 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. 4. This Statement includes the results of the Holding Company and the following entities: Sr. No Name of the Entit Re lat an 1 Neu land Laboratories K. K., Ja an Wholl 2 Neuland Laboratories Inc. USA Wholl wned Subsid 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 I LLPIN: ACT-3789 Ahmed<1bad I Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Gurugram I Kochi I Kolkata I Mumbai I Pune www mska,in
Page 3
MSKA & Associates LLP (Formerly known as M 5 KA 8: Associates) Chartered Accountants 6. The Statement includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total assets of Rs.1,264. 32 as at September 30, 2026 and total revenue of Rs. 1,024.99 lakhs and Rs.1,631.53 lakhs, total net profit after tax of Rs. 49. 75 lakhs and Rs.80.87 lakhs and total comprehensive income of Rs. 35.26 lakhs and Rs.57.48 lakhs for the quarter ended September 30, 2026, and for the period from April 01, 2026, to September 30, 2026, respectively, and cash flows (net) of Rs. 162.79 Lakhs for the period from April 01, 2026, to September 30, 2026, as considered in the Statement. This interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of the above matter with respect to our reliance on the interim financial information certified by the management. For M S K A & Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants ICA~ irm Registration No.105047W/W101187 ·ir ~ Pra ashChandra Bhutada Partner Membership No.: 404621 uo1N: 2~ l/o Yb~. I Mt en-/ R ~~9b Place: Hyderabad Date: November 03, 2026 Registered Office: 602, Raheja nt,mium, Western Express Highway, Goregaon (East), Mumbai·400063, Maharashtra, India Tel: +91 22 6974 0200 I LLPIN: ACT•3789 Ahmec!abad I Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Gurugram I Hyderabad I Koehl I Kolkata I Mumbai I Pune www mska in
Page 4
SI, No. 1 2 3 4 5 6 7 8 9 Nculand Laboratories Limited 11th floor (5th level), Phoenix IVY Building, Plot No.573A-lil, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. c, TA 040 6761 1600 / 6761 1100 neuland@neulandlabs.com neulandlabs.com NEULAND LABORATORIES LIMITED 11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad• 500033 /{ neuland STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 (Amount in lakhs of 'I', unless otherwise stated) Quarter Ended Half Year Ended Year Ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09,2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Income (a) Revenue from operations 44,965.69 64,157.71 51,427.31 1,09, 123.40 80,702.58 2,02,298.54 (b) Other income 749.53 849.17 179.97 1,598.70 965.56 3,016.62 Total Income 45,715.22 65,006.88 51,607.28 1, 10,722.10 81,668.14 2,05,315.16 Expenses (a) Cost of materials consumed 21,578.73 22,876.92 22,764.00 44,455.65 38,912.04 81,976.45 (b) Changes in inventories of finished goods and work-in-progress (6,473.15) (774.54) (4,403.10) (7,247.69) (9,196.75) (6,426.23) (c) Employee benefits expense 10,175.87 10,642.92 8,037.23 20,818.79 15,383.74 34,114.14 (d) Finance costs 730.73 697.19 536.71 1,427.92 995.20 2,394.74 (e) Depredation and amortisation expenses 2,877.13 2,656.32 2,254.15 5,533.45 4,273.10 9,173.95 (f) Manufacturing expenses 5,780.43 4,793.57 4,595.62 10,574.00 8,533.10 19,161.44 (11) Other expenses 4,147.66 4,329.80 4,879.02 8,477.46 8,067.02 16,022.96 Total expenses 38,817.40 45,222.18 38,663.63 84,039.58 66,967.45 1,56,417.45 Profit before tax (1·2) 6,897.82 19,784.70 12,943.65 26,682.52 14,700.69 48,897.71 Tax expense (a) Current tax 1,786.79 5,088.03 3,251.25 6,874.82 3,687.93 12,895.54 (b) Deferred tax (credit)/charge (51.47) (70.64) 7.01 (122.11) (62.63) (397.67) Profit for the period I year (3-4) 5,162.50 14,767.31 9,685.39 19,929.81 11,075.39 36,399.84 Other comprehensive income/(loss) (net of taxes) (a) Items that will not be reclassified to profit or loss Re-measurement gain on defined benefit plans (27.57) (39.11) (27.57) (39.11) 1.65 Changes in fair value of equity instruments through other 45.33 comprehensive income Tax on items that will not be reclassified to profit or loss 6.94 9.84 6.94 9.84 (11.82) (b) Items that will be reclassified to profit or loss Exchange differences in translating the financial statements of (14.49) (8.90) 18.44 (23.39) 28.36 71.25 foreign operations Total comprehensive income 5,127.38 14,758.41 9,674.56 19,885.79 11,074.48 36,506.25 Paid-up Equity Share Capital (Face value· "'10 each) 1,290.05 1,290.05 1,290.05 1,290.05 1,290.05 1,290.05 Other equity (excluding revaluation reserve) 1,86,073.35 Eaminas Per Share (of '1'10 each) (In absolute"' tenms) Basic and Diluted (Refer Note 5) 40.24 115.10 75.49 155.34 86.32 283.71 See accompanying notes to the financial results NOTES: 1 The financial results for the quarter and half year ended September 30, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 03, 2026. The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2026. 2 The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS} 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The consolidated financial results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA (b) Neuland Laboratories KK., Japan. REGISTERED OFFICE: 11th floor (5th level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CIN No. L85195TG1984PLC004393
Page 5
/{ neuland ◄ Segment Reportin11 Quarter Ended Half Year Ended Year Ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Segment Revenue India 7,822.97 8,326.38 17,208.70 16,149.35 27,101.32 48,409.19 Europe 20,009.81 30,345.81 16,242.92 50,355.62 25,684.15 67,544.32 USA and North America 12,887.54 19,967.36 14,218.34 32,854.90 20,796.71 71,345.10 Rest of the world 4,245.37 5,518.16 3,757.35 9,763.53 7,120.40 14,999.93 Revenue from Operations 44,965.69 64,157.71 51,427.31 1,09, 123.40 80,702.58 2,02,298.54 As At Particulars 30.09.2026 31.03.2026 Segment Non•current assets India 1,62,378.84 1,43,305.04 USA and North America Rest of the world 3.46 2.82 Total 1,62,382.30 1,43,307.86 i. Segment information presented for the "Consolidated financial results· as permitted under the Ind A5 • 'Operating Segments'. ii. The management has assessed the identification of reportable segments in accordance with the requirements of Ind A5 108 'Operating Segment' and believes that the Group has only one reportable segment namely "manufacture of active pharmaceutical ingredients and allied services". Geography-wise details of the Company's revenues from external customers and its non-current assets (excluding financial assets) are disclosed above. 5 The EPS for quarters has not been annualised.
Page 6
Ji neuland NEULAND LABORATORIES LIMITED STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026 (Amount in lakhs of"'• unless otherwise stated) Particulars 30.09.2026 31.03.2026 (Unaudited) (Audited) ASSETS Non•current assets Property, plant and equipment 90,161.59 79,341.51 Right-of-use assets 9,257.55 9,887.25 Capital wor1<-in-pr011ress 28,429.54 20,949.90 Goodwill 27,946.10 27,946.10 Other intangible assets 386.16 518.12 Intangible assets under development 45.64 108.46 Financial assets (i) Investments 198.22 198.22 (ii) Other financial assets 1,390.01 1,194.81 Income tax assets (net) 216.23 396.27 Other non•current assets 5,939.49 4,160.25 Total non~current assets 1,63, 970.53 1,44,700.89 Current assets Inventories 55,210.02 51,028.64 Financial assets (i) Trade receivables 29,430.40 54,135.31 (ii) Cash and cash equivalents 5,365.54 7,667.04 (iii) Bank balances other than cash and cash equivalents 39,678.28 27,829.45 (iv) Other financial assets 1,454.36 433.81 Other current assets 7,846.70 7,218.63 Total current assets 1,38, 985.30 1,48,312.88 Total assets 3,02,955.83 2, 93,013.77 EQUITY AND LIABILITIES Equity Equity share capital 1,290.05 1,290.05 Other equity 2,01 ,680.91 1,86,157.24 Total equity 2,02,970.96 1,87,447,29 Liabilities Non-current liabilities Financial liabilities (i) Borrowings 20,072.16 16,094.73 (ia) Lease liabilities 9,560.96 9,969.48 Provisions 1,694.86 1,586.11 Deferred tax liabilities (net) 6,799.25 6,896.36 Total non-current liabilities 38,127.23 34,546.68 Current liabilities Financial liabilities (i) Borrowings 3,848.22 3,566.58 (ia) Lease liabilities 749.38 496.43 (ii) Trade payables -total outstanding dues of micro enterprises and small enterprises 1,451.79 1,264.29 -total outstanding dues of creditors other than micro enterprises and small enterprises 19,409.83 25,650.12 (iii) Other financial liabilities 11,266.60 12,678.26 Provisions 309.37 230.78 Other current liabilities 23,630.11 25,317.78 Current tax liabilities (net) 1,192.34 1,815.56 Total current liabilities 61,857.64 71,019.80 Total liabilities 99,984.87 1,05,566.48 Total equity and liabilities 3,02,955.83 2,93,013.77
Page 7
Cash flow from operating activities Profit before tax Adjustments to reconcile profit before tax to net cash flow: Depreciation and amortisation expenses Interest income Loss on sale of property, plant and equipment, net Finance costs Provision towards credit impaired trade receivables Gain on redemption of investments carried at FVTPL Unrealised foreign exchange loss/ (gain), net Operating cash flows before working capital changes Movements In working capital: Adjustments for (increase)/decrease in operating assets: Inventories Trade receivables Other financial assets Other assets Adjustments for increase/(decrease) in operating liabilities: Trade payables Other financial liabilities Provision for employee benefits Other liabilities Cash 1enerated from operatlna activities Income-taxes paid (net) Net cash(used In)/ flow from operating activities (A) Cash flows from invest!n1 activities NEULAND LABORATORIES LIMITED CONSOLIDATED STATEMENT OF CASH FLOWS Particulars Purchase of property, plant and equipment and other intangible assets Proceeds from sale of property, plant and equipment Movement in other bank balances (net) Interest income received Net cash used in investing activities (B) Cash flows from financing activities Proceeds from non-current borrowings Repayment of non-current borrowings Proceeds from short-term borrowings (net) Finance cost paid Dividend paid Payment of lease liabilities Interest on lease liabilities Net cash used in financfn1 activities (C) Net decrease in cash and cash equivalents during the period (A + B + C) Cash and cash equivalents at the beginning of the period Effects of exchange rate changes on cash and cash equivalents Cash and cash equivalents at the end of the period Place: Hyderabad Date: November 03, 2026 I{ neuland (Amount in lakhs of'\', unless otherwise stated) Half Year Ended 30.09.2026 30.09.2025 Unaudited) (Unaudited) 26,682.52 14,700.69 5,533.45 4,273.10 (1,598.62) (518.59) 235.40 134.18 1,427.93 995.20 37.09 6.47 (446.97) (365.39) 697.53 31,952.38 19,841.61 (4,181.38) (16,214.13) 24,608.84 (12,318.90) (512.13) (1,669.34) (631.18) (2,763.80) (5,874.42) 3,404.68 (392.12) (897.70) 159.77 (9.37) (1,687.65) 10,944.53 43,442.11 317.58 (7,286.06) (3,992.26) 36,156.05 (3,674.68) (26,059.89) (17,074.60) 22.05 43.84 (11,850.38) 11,169.38 896.55 641.88 (36,991.67) (5,219.50) 6,794.04 1,774.03 (2,289.53) (2,345.16) 3,000.00 (959.72) (776.58) (4,362.17) (1,539.59) (155.56) (84.43) (470.12) (221.31) (1,443.06) (193.04) (2,278.68) (9,087.22) 7,667.04 13,193.04 (22.82) 28.36 5,365.54 4,134.18 ~~Limited Dr.DR Rao Executive Chairman (DIN 00107737)
Page 8
MSKA Et Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants 1101 /B, Manjeera Trinity Corporate JNTU-Hitech City Road, Kukatpally Telangana, Hyderabad 500072, INDIA Independent Auditor's Review Report on Standalone unaudited financial results of Heuland Laboratories Limited for the quarter and year to date pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Heuland Laboratories Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Neuland Laboratories Limited ("the Company") for the quarter ended September 30, 2026 and year to-date results for the period from April 01, 2026 to September 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations"). 2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For MS KA & Associates LLP (Formerly known as M s KA & Associates) Chartered Accountants ICA(hm_ ~eg~stration No. 105047W /W101187 ~'t . Prakash Chandra Bhutada Partner Membership No.: 404621 UDIN: 2 b~ o y b .Z I Yt.f Q lJ'1J115 Place: Hyderabad Date: November 03, 2026 Registered Offic.e: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Murnbai-400063, Maharashtra, India Tel: +91 22 6974 0200 I LLPIN: ACT-3789 Ahmedal:>ad I Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Gurugrarn I Kochi I Kolkato I Muml:>ai I Pune www. m:;ka )I]
Page 9
SI. No. 1 2 3 4 5 6 7 8 9 Neuland Laboratories Limited 11th floor (5th level), Phoenix IVY Building, Plot No.573A-llI, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CONTACT 040 67611600 / 67611700 neuland@neulandlabs.com neulandlabs.com NEULAND LABORATORIES LIMITED 11th Floor (5th Office Level), Phoenix IVY Building, Plot Ho. 573A-III, Road Ho 82, Jubilee HIiis, Hyderabad • 500033 I{ neuland STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YIEAR ENDED SEPTEMBER 30, 2026 (Amount in lakhs of\', unless otherwise stated) Quarter Ended Half Year Ended Year Ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Income (a) Revenue from operations 44,965.69 64,157.71 51,427.31 1,09, 123.40 80,702.58 2,02,298.54 (b) Other income 749.34 849.17 179.87 1,598.51 965.46 3,016.39 Total Income 45,715.03 65,006.88 51,607.18 1, 10,721.91 81,668.04 2,05,314.93 Expenses (a) Cost of materials consumed 21,578.73 22,876.92 22,764.00 44,455.65 38,912.04 81,976.45 (b) Changes in inventories of finished goods and work-in-progress (6,473.15) (774.54) (4,403.10) (7,247.69) (9,196.75) (6,426.23) (c) Employee benefits expense 9,505.25 10,302.43 7,667.84 19,807.68 14,756.08 32,882.04 (d) Finance costs 730.54 697.19 534.12 1,427.73 992.45 2,394.54 (e) Depreciation and amortisation expenses 2,876.85 2,656.09 2,253.92 5,532.94 4,272.64 9,173.05 (f) Manufacturing expenses 5,780.43 4,793.57 4,595.62 10,574.00 8,533.10 19,161.44 (g) Other expenses 4,868.31 4,701.64 5,290.64 9,569.95 8,756.54 17,380.33 Total expenses 38,866.96 45,253.30 38,703.04 84,120.26 67,026.10 1,56,541.62 Profit before tax (1-2) 6,848.07 19,753.58 12,904.14 26,601.65 14,641.94 48,773.31 Tax expense (a) Current tax 1,786.79 5,088.03 3,251.25 6,874.82 3,687.93 12,888.35 (b) Deferred tax charge / (credit) (51.47) (70.64) 7.01 (122.11) (62.63) (425.54) Profit for the period I year (3-4) 5,112.75 14,736.19 9,645.88 19,848.94 11,016.64 36,310.50 Other comprehensive income (net of taxes) Items that will not be reclassified to profit or loss Re-measurement gain/(loss) on defined benefit plans (27.57) (39.11) (27.57) (39.11) 1.65 Changes in fair value of equity instruments through other 45.33 comprehensive income Tax on items that will not be reclassified to profit or loss 6.94 9.84 6.94 9.84 (11.82) Total comprehensive Income 5,092.12 14,736.19 9,616.61 19,828.31 10,987.37 36,345.66 Paid-up Equity Share Capital (Face value -f10 each) 1,290.05 1,290.05 1,290.05 1,290.05 1,290.05 1,290.05 Other equity (excluding revaluation reserve) 1,85,211.19 Earnings Per Share (of ~10 each) (In absolute~ terms) Basic and Diluted (Refer Note 4) 39.85 114.86 75.18 154.71 85.87 283.01 See accornpanylns notes to the financial results NOTES: 1 The financial results for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 03, 2026. The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2026. 2 The financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3 The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments". In accordance with Ind AS 108 -'Operating segments·, segment information has been given in the unaudited consolidated financial results of the Company and therefore no separate disclosure on segment information is given in these unaudited standalone financial results. 4 The EPS for quarters has not been annualised. REGISTERED OFFICE: 11th floor (5th level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CIN No. L85195TG1984PLC004393
Page 10
/{ neuland NEULAND LABORATORIES LIMITED STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026 (Amount in lakhs of , , unless otherwise stated) Particulars 30.09.2026 31.03.2026 (Unaudited) (Audited) ASSETS Non-current assets Property, plant and equipment 90,158.70 79,339.67 Right-of-use assets 9,257.55 9,887.25 Capital work-in-progress 28,429.54 20,949.90 Goodwill 27,946.10 27,946.10 Other intangible assets 386.16 518.12 Intangible assets under development 45.64 108.46 Financial assets (i) Investments 214.04 214.04 (ii) Other financial assets 1,372.66 1,177.92 Income tax assets (net) 216.23 396.27 Other non-current assets 5,938.91 4,159.27 Total non-current assets 1,63,965.53 1,44,697.00 Current assets Inventories 55,210.02 51,028.64 Financial assets (i) Trade receivables 29,430.40 54,135.31 (ii) Cash and cash equivalents 5,067.09 7,530.81 (iii) Bank balances other than cash and cash equivalents 39,678.28 27,829.45 (iv) Other financial assets 1,454.36 433.81 Other current assets 7,835.40 7,178.76 Total current assets 1,38,675.55 1,48, 136.78 Total assets 3,02,641.08 2, 92,833.78 EQUITY AND LIABILITIES Equity Equity share capital 1,290.05 1,290.05 Other equity z.oo. 761.22 1,85,295.08 Total equity 2,02,051.27 1,86,585.13 Lfabilitles Non-current liabilities Financial liabilities (i) Borrowings 20,072.16 16,094.73 (ia) Lease liabilities 9,560.96 9,969.48 Provisions 1,616.14 1,517.73 Deferred tax liabilities (net) 6,613.30 6,742.35 Total non-current liabllitles 37,862.56 34,324.29 Current lfabllities Financial liabilities (i) Borrowings 3,848.22 3,566.58 (ia) Lease liabilities 749.38 496.43 (ii) Trade payables • total outstanding dues of micro enterprises and small enterprises 1,451.79 1,264.29 • total outstanding dues of creditors other than mkro enterprises and small enterprises 20,343.60 26,601.81 (iii) Other financial liabilities 11,250.99 12,642.35 Provisions 309.37 230.78 Other current liabilities 23,580.89 25,309.40 Current tax liability (net) 1,193.01 1,812.72 Total current liabilities 62,727.25 71,924.36 Total liabilities 1,00,589.81 1,06,248.65 Total equity and liabilities 3,02,641.08 2, 92,833.78
Page 11
NEULAND LABORATORIES LIMITED STANDALONE STATEMENT OF CASH FLOWS Particulars Cash flow from operating activities Profit before tax Adjustments to reconcile profit before tax to net cash flow: Depreciation and amortisation expenses Interest income Loss on sale on property, plant and equipment, net Finance costs Provision towards credit impaired trade receivables Gain on redemption on investments carried at MPL Unrealised foreign exchange loss/(gain), net Operating cash flows before working capital changes Movements fn working capital: Adjustments for (increase)/decrease in operating assets: Inventories Trade receivables Other financial assets Other assets Adjustments for increase/(decrease) in operating liabilities: Trade payables Other financial liabilities Provision for employee benefits Other liabilities Cash generated from operating activities Income-taxes paid (net) Net cash (used in)/flow from operating activities (A) Cash flows from investing activities Purchase of property, plant and equipment and other intangible assets Proceeds from sale of property, plant and equipment Movement in other bank balances (net) Interest income received Net cash used in Investing activities (B) Cash flows from financing activities Proceeds from non-current borrowings Repayment of non-current borrowings Proceeds of short-term borrowings Finance cost paid Dividend paid Payment of lease liabilities Interest on lease liabilities Net cash used in financing activities (C) Net decrease In cash and cash equivalents during the period (A + B + C) Cash and cash equivalents at the beginning of the period Effect of exchange rate changes on cash and cash equivalents Cash and cash equivalent• at the end of the period • Place: Hyderabad Date: November 03, 2026 ... vv -- /{ neuland (Amount in lakhs of~. unless otherwise stated) Half Year Ended 30.09.2026 30.09.2025 /Unaudited) /Unaudited) 26,601.65 14,641.94 5,532.94 4,272.64 (1,598.43) (518.49) 235.40 134.18 1,427.73 992.45 37.09 6.47 (446.97) (365.39) 697.53 31,870.99 19,779.75 (4,181.38) (16,214.13) 24,608.84 (12,318.90) (511.67) (1,668.40) (660.16) (2,764.88) (5,892.34) 3,354.09 (371.81) (785.43) 149.43 (17.81) (1,728.53) 10,954.73 43,283.37 319.02 (7,314.49) (3,988.46) 35,968.88 (3,669.◄4) (26,058.34) (17,074.29) 22.05 43.84 (11,850.38) 11,169.38 896.36 641.78 (36,990.31) (5,219.29) 6,794.04 1,774.03 (2,289.53) (2,345.16) 3,000.00 (959.52) (773.83) (4,362.17) (1,539.59) (155.56) (84.43) (◄70.12) (221.31) (1,442.86) (190.29) (2,464.29) (9,079.02) 7,530.81 13,037.90 0.57 5,067.09 3,958.88 For Neuland Laboratories Llmlte<:1.. ~ ~y-~I& Dr. D R Rao ,, / l1}m_ Executive Cha!rrnap • HYDERA' (DIN 00107737) \ VJ